logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9351927 B1

PDFFull Text
Expired
Date of Patent:
May. 31, 2016

Filed:

Jul. 02, 2010

Pharmaceutical compositions for treatment of patients with neurodegeneration following ischemic insult

Applicants:

William H. Frey, Ii, White Bear Lake, MN (US);

Samuel Scott Panter, San Francisco, CA (US);

Leah Ranae Bresin Hanson, Vadnais Heights, MN (US);

Annina Roeytenberg, San Francisco, CA (US);

Inventors:

William H. Frey, II, White Bear Lake, MN (US);

Samuel Scott Panter, San Francisco, CA (US);

Leah Ranae Bresin Hanson, Vadnais Heights, MN (US);

Annina Roeytenberg, San Francisco, CA (US);

Assignee:

HealthPartners Researh Foundation, Bloomington, MN (US);

Attorney:

Barnes & Thornburg LLP

Primary Examiner:

Daniel E Kolker

Assistant Examiner:

Stacey N MacFarlane

Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/165 (2006.01); A61K 38/16 (2006.01); A61K 38/28 (2006.01); A61K 31/195 (2006.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 38/30 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0043 (2013.01); A61K 31/165 (2013.01); A61K 31/195 (2013.01); A61K 38/1841 (2013.01); A61K 38/2006 (2013.01); A61K 38/28 (2013.01); A61K 38/30 (2013.01); A61K 45/06 (2013.01); A61K 2800/522 (2013.01);
Abstract

Pharmaceutical compositions for treating and/or pre-treating or preconditioning the animal central nervous system against the effects of Alzheimer's Disease including the associated neurodegeneration and cognitive, behavioral and physical impairments. In one embodiment, an effective dose of deferoxamine (DFO) is administered to the upper one-third of the subject patient's nasal cavity to effectively bypass the blood-brain barrier, thereby allowing application of the DFO dose directly to the central nervous system.

Find Patent Forward Citations

Quick Actions:

Frey, II, William. (2016). Pharmaceutical compositions for treatment of patients with neurodegeneration following ischemic insult (U.S. Patent No. 9351927). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9351927

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…